Pridopidine (ACR16) belongs to a new pharmacological class of agents affecting the central nervous system called dopaminergic stabilizers. Dopaminergic stabilizers act primarily at dopamine type 2 (D 2 ) receptors and display state-dependent behavioural effects. This article aims to give an overview of the preclinical neurochemical and behavioural in vivo pharmacological properties of pridopidine. Pridopidine was given s.c. to male Sprague-Dawley rats (locomotor, microdialysis and tissue neurochemistry) and i.p. to Swiss male mice (tail suspension test). Pridopidine dose-dependently increased striatal tissue levels of the dopamine metabolite 3,4-dihydroxyphenylalanin (ED 50 = 81 μmol/kg), and prefrontal cortex dialysate levels of dopamine and noradrenaline as measured by high performance liquid chromatography. The agent reduced hyperlocomotion (D-amphetamine: ED 50 = 54 μmol/kg; MK-801: ED 50 = 40 μmol/kg), but preserved spontaneous locomotor activity, confirming state-dependent behavioural effects. In addition, pridopidine significantly reduced immobility time in the tail suspension test. We conclude that pridopidine state-dependently stabilizes psychomotor activity by the dual actions of functional dopamine D 2 receptor antagonism and strengthening of cortical glutamate functions in various settings of perturbed neurotransmission. The putative restoration of function in cortico-subcortical circuitry by pridopidine is likely to make it useful for ameliorating several neurological and psychiatric disorders, including Huntington's disease.
Introduction
Pridopidine (ACR16; 4-[3-(methylsulfonyl)phenyl]-1-propylpiperidine hydrochloride; Huntexil ® ), originally referred to as a modulator of dopamine neurotransmission (Sonesson et al., 2000) , belongs to a new pharmacological class of agents acting on the central nervous system. Through their primary action at dopamine type 2 (D 2 ) receptors, these compounds stabilize dysregulated psychomotor functions (i.e. they reverse behavioural states originating from both hypo-and hyper-dopaminergia), while having only subtle effects on normal psychomotor activity (Natesan et al., 2006; Pettersson et al., 2010; Sonesson et al., 2000) . Thus, these compounds regulate both hyper-and hypoactive functioning in areas of the brain receiving dopamine input, leading to reduced excitatory and inhibitory stress, resulting in improved behavioural performance. These pharmacodynamic actions of this new class (known as dopaminergic stabilizers) do not appear to fit fully into the current classification of dopamine D 2 receptor-acting compounds (Carlsson, 2000; Rung et al., 2008) : antagonists, agonists, partial agonists or inverse agonists (Strange, 2008) .
Pridopidine has been shown to bind to striatal dopamine D 2 receptors in vivo, in a dose range where the agent is active in models assessing antipsychotic-like efficacy, and, similar to dopamine D 2 receptor antagonists, lacks intrinsic activity at dopamine D 2 receptors in vivo (Natesan et al., 2006) as well as in vitro (Dyhring et al., 2010; Tadori et al., 2007) . The functional effects of dopaminergic stabilizers are not confined to aberrations originating from the dopamine system. Pridopidine has also been shown to reverse perturbed behavioural patterns originating from hypoglutamatergic states induced by the N-methyl-D-aspartate (NMDA) receptor antagonist MK-801 (Nilsson et al., 2004; Pettersson et al., 2002; Rung et al., 2005; Waters et al., 2002) . In line with this, increased expression of the gene encoding the activity-regulated cytoskeletal protein (Arc) has been observed in rat cortex after acute systemic administration of pridopidine, which is probably the result of synaptic NMDA receptor activation (Waters et al., 2009a) . Hence, at the system level, pridopidine is hypothesized to have a dual mechanism of action consisting of both functional modulation of dopamine transmission and activation of cortical glutamate transmission through synaptic NMDA receptors. Current theories implicate aberrant dopamine transmission in disorders such as schizophrenia, Huntington's disease (HD) and Parkinson's disease (PD) . However, there are suggestions that glutamate transmission, for example at the NMDA receptor subunit NR2B, might also be involved in these disorders, for review see Loftis and Janowsky (2003) . Furthermore, pharmacological therapies targeting the glutamate system that aim to modulate transmission at NMDA receptors are hypothesized to be useful in schizophrenia (Kim et al., 2009) , PD (Johnson et al., 2009) and HD (Frank and Jankovic, 2010) . Based on hypotheses regarding the mode of action of pridopidine and putative treatment opportunities, clinical trials have been initiated and show encouraging results in patients with PD (Tedroff et al., 2004) , schizophrenia (Carlsson and Carlsson, 2006) and HD (Tedroff et al., 2009) . Pridopidine is currently in clinical development for the treatment of HD.
The aim of this article is to give an overview of the preclinical in vivo pharmacological studies performed during the discovery of pridopidine. The data have previously been published, in part, in article, patent, poster and abstract form Pettersson et al., 2002; Sonesson et al., 2000; Waters et al., 2002; Waters et al., 2009a) .
Materials and methods

Animals
Male Sprague-Dawley rats from B&K Scanbur were used for locomotor, tissue neurochemistry and microdialysis studies. Rats weighed 160-180 g at the time of arrival. Rats weighed 220-270 g at the time of the locomotor and tissue neurochemistry studies and 240-355 g at the time of microdialysis studies. They were housed five animals per cage with lights on between 06:00 h and 18:00 h. Swiss male mice from Depré, France (weighing 19-24 g) were used for the tail suspension tests. All experiments were carried out in accordance with the European Community guidelines for animal studies and with the approval of local animal ethics committees.
Locomotor activity
Locomotor activity was recorded for 60 min in motility meters generating a time series of x, y (horizontal activity) and z (vertical activity) coordinates sampled at 25 Hz. This time series was subsequently converted into locomotor variables studied at seven frequencies from 25 Hz to 0.25 Hz (Ponten et al., 2005) . For the statistical analysis applied in the present article, only the variable distance, derived from the highest frequency (25 Hz), was used. Pridopidine was administered using the NeuroSearch Sweden AB standard screening protocol for investigation of novel compounds, consisting of subcutaneous (s.c.) injection 4 min before initiation of locomotor recordings. D-amphetamine (1.5 mg/kg) and MK-801 (0.7 mg/kg) were injected intraperitoneally (i.p.) 6 and 86 min, respectively, before s.c. administration of pridopidine. Our laboratory has found that these doses and timings of D-amphetamine and MK-801 administration produce locomotor behavioural patterns with a high degree of inter-trial reproducibility. In the habituated-state experiments, the animals were placed in the motility meter arena for 30 min to allow habituation before s.c. injection of pridopidine and start of locomotor recordings.
Ex vivo tissue preparation and analysis
Animals were decapitated 64 min after drug administration and brains dissected into striatum, cortex and limbic regions (containing the nucleus accumbensboth the core and shellmost parts of the olfactory tubercle and ventral pallidum). The tissue samples were frozen immediately and stored at -80°C before preparation, see Ponten et al. (2005) for further details. Alpha-methyl-dopa (0.25 μM) was used as internal standard in high performance liquid chromatography analysis with electrochemical detection (HPLC/EC) of tissue eluates. The separation of the monoamine transmitter substances (noradrenaline, dopamine, 5-hydroxytryptamine [5-HT]) as well as the amine metabolite, 3-methoxytyramine (3-MT) and acid metabolites (3, , 5-hydrocyindoleacetic acid [5-HIAA], homovanillic acid [HVA]) was performed on a reverse phase column (Nucleosil ODS, 5 μm, 150 × 4.6 mm internal diameter) with an aqueous mobile phase (1 ml/min) containing 40 mM citric acid, 12 mM K 2 HPO 4 , 1.7 mM H 3 PO 4 , 0.35 mM sodium octylsulfate, 6% (volume/volume) of methanol and 0.05 mM EDTA.
Microdialysis
Experiments were conducted in accordance with Waters et al. (1993) , with some modifications as described below. For experiments performed in the dorsal striatum, prefrontal cortex and nucleus accumbens, probes with an exposed length of 3, 2.5 and 2 mm of the dialysis membrane, respectively, were used. Coordinates were calculated relative to bregma: prefrontal cortex (antero-posterior, + 3.2 mm from bregma; medio-lateral, 1.2 mm from midline; and dorsal-ventral, -4.0 mm from the surface of skull), nucleus accumbens (antero-posterior, + 1.85 mm; mediolateral, 1.6 mm; dorsal-ventral, -7.8 mm) or dorsal striatum (antero-posterior + 1.0 mm; medio-lateral, 2.6 mm; dorsal-ventral, -6.2 mm) according to Paxinos and Watson (1986) . The probe directed at the prefrontal cortex was angled 8°from the midsagittal plane. Before insertion into the brain, the dialysis probes were perfused with 0.6 ml ethanol 70% and 1 ml of Ringer solution consecutively. The rats were housed individually in spherical cages for 36 to 48 h before the dialysis experiments. The brains were removed rapidly and fixed in Neo-fix solution (Kebo-lab, Sweden). Determination of dialysate content of dopamine, noradrenaline, 5-HT, DOPAC, HVA, 3-MT and 5-HIAA was performed in accordance with the HPLC/EC system described in Ponten et al. (2005) .
Tail suspension test
Four groups of 10 mice each were used for tail suspension tests. The first group received saline vehicle, the second desipramine 10 mg/kg (as method control substance), and groups three and four received pridopidine (10 μmol/kg and 40 μmol/kg, respectively). Given that the initial pharmacokinetic and pharmacological exploration of pridopidine in mice was performed using i.p. administration, each agent was also administered i.p. for the tail suspension test. The mice were observed at about 27 min after dosing to confirm that treatment had no marked effect on normal behaviour and at 30 min after dosing were suspended by their tail in the cage. The sum of immobility periods was recorded over a period of 6 min. Experiments were performed by Centre de Recherches Biologiques (CERB), France.
Data analysis
Data are expressed as mean ± S.E.M. percentage of vehicle-treated group in the normal state and the habituated state, and as mean± S.E.M. percentage of the D-amphetamine or MK-801 pretreated controls in the D-amphetamine and MK-801 state experiments, respectively. The ED 50 values for DOPAC in striatum and locomotor activity were calculated by curve fitting and fitted by least square minimization to the function: End-(End-Control)/(1+ (dose/ED 50 ) Slope ), where Control is control level and End is end level. The DOPAC levels were normalized to control (within each experiment), ED 50 and slope were fitted with the restrictions: ED 50 N 0, 0.5 b Slopeb 3, End = 350% of control. For ED 50 value calculation of pridopidine-induced reduction of spontaneous or drug-induced hyperlocomotion by D-amphetamine or MK-801, distances were normalized to vehicle, D-amphetamine or MK-801 controls, respectively, and fitted with the restrictions: ED 50 N 0, 0.5 b Slope b 3, End= 0% of control. In addition, statistical significance was assessed versus appropriate control groups using the Student's ttest. ED 50 and t-tests were calculated using Excel (Microsoft) .
Microdialysis data are expressed as the mean ± S.E.M. percentage of baseline. Baseline was defined as the mean of the three fractions immediately before administration of test compound. Data were analysed using Statview (SAS Institute) by repeated measures analysis of variance (ANOVA), and if significant effects were found, followed by Fischer's PLSD post hoc test.
Total immobility time in the tail suspension tests are expressed as medians with ranges and were analysed by the non-parametric Mann-Whitney U test.
For all tests, P b 0.05 was considered significant.
Drugs
Pridopidine HCl salt (molecular weight 317.88) was synthesized internally at NeuroSearch Sweden AB. MK-801 (dizocilpine) and desipramine HCl was obtained from Sigma-Aldrich. D-amphetamine was obtained from AKL (Sweden). All compounds were dissolved in physiological saline (0.9 wt.%/volume NaCl) and injected in a volume of 5 ml/kg, with the exception of the tail suspension tests in which agents were injected in a volume of 10 ml/kg.
Results
Ex vivo brain monoaminergic biochemistry
The main effects observed in rats were dose-dependent increases of the dopamine metabolites DOPAC and HVA in the cortical, striatal and limbic regions ( Fig. 1; Table 1 ). In the striatum, DOPAC increased to approximately 300% of the vehicle control at 300 μmol/kg s.c. The ED 50 value for increase in striatal DOPAC was calculated to be 81 μmol/kg of pridopidine (Table 2) . Pridopidine induced decreases in dopamine, noradrenaline and 5-HT in ex vivo brain tissue. The decreases in 5-HT were less prominent and reached significance only in the striatum, where it decreased to 88% of vehicle group at 100 μmol/kg s.c. (Table 1) .
Microdialysis
The main effects of pridopidine were dose-dependent increases in the extracellular levels of dopamine, noradrenaline, DOPAC, HVA, 3-MT and 5-HIAA in the nucleus accumbens, dorsal striatum and prefrontal cortex; by contrast, 5-HT increased significantly (up to 126% of the vehicle control) only in prefrontal cortex (Fig. 2 , Table 3 ). At 50 μmol/kg of pridopidine, dopamine increased significantly to 194%, 173% and 212% of the vehicle control, and noradrenaline to 157%, 300% and 209% of the vehicle control in the nucleus accumbens, dorsal striatum and prefrontal cortex, respectively. 3-MT, 3-methoxytyramine; 5-HIAA, 5-hydroxyindoleacetic acid; 5-HT, 5hydroxytryptamine; DOPAC, 3,4-dihydroxyphenylalanine; HVA, homovanillic acid; n. d., not determined. a P b 0.05, b P b 0.01 and c P b 0.001. 
Locomotor activity
3.3.1. In the normal state In normal rats without pretreatment, pridopidine had only subtle locomotor effects at doses up to 300 μmol/kg s.c., and significant effects were not noted when data were pooled for the full hour of recording (Fig. 3) . However, during the most intensive exploratory phase (0-15 min), the highest dose tested (300 μmol/kg) decreased locomotor activity to 58% of the vehicle-treated control group. When the rats had become partially habituated to the motility meter arena (15-60 min after dosing), pridopidine tended to increase locomotor activity, and a significant stimulant effect, 231% of vehicle, was seen at 100 μmol/kg. ED 50 for reduction of spontaneous locomotor reduction 0-15 min was calculated to be 318 μmol/kg s.c. (95% confidence interval [CI]: 248-566) ( Table 2 ). Data did not support calculation of an ED 50 for reduction of locomotor activity 15-60 min or 0-60 min.
In the habituated state
In animals that had been habituated to the motility meter arena for 30 min before administration of pridopidine, a significant locomotor stimulation, to 931% of vehicle-treated control group, was induced by the 50 μmol/kg dose during 15-60 min of locomotor recording (Fig. 4) .
In the D-amphetamine hyperactive state
The hyperactivity induced by D-amphetamine (1.5 mg/kg i.p.) was dose-dependently reduced during 15-60 min of recording by pridopidine at 50 and 150 μmol/kg s.c. (Fig. 5A) . The ED 50 for the reduction of D-amphetamine-induced hyperactivity during15-60 min was calculated to be 54 μmol/kg of pridopidine (Table 2) .
In the MK-801 hyperactive state
Pridopidine dose-dependently reversed the behavioural hyperactivity induced by MK-801 (0.7 mg/kg i.p.) during 15-60 min at 50 and 150 μmol/kg s.c. (Fig. 5B) . The ED 50 for reduction of MK-801 induced hyperlocomotion during 15-60 min was calculated to 40 μmol/kg of pridopidine (Table 2) .
Tail suspension test
The median immobility time in mice receiving vehicle was 42 seconds (range: 30-114 s). Corresponding data for animals receiving pridopidine 10 or 40 μmol/kg were 10 seconds (range: 0-55 s) and 22 s (1-74 s), respectively. The variation from vehicle was significant for both doses of pridopidine (10 μmol/kg: P b 0.01; 40 μmol/kg: P b 0.05) demonstrating an antidepressant-like effect. In comparison, desipramine 10 mg/kg was associated with an immobility time of 21 s (range: 0-38 s).
Discussion
Dopaminergic stabilizers as a concept
The concept of dopaminergic stabilizers has been present in the literature for about a decade. Pridopidine (ACR16) was discovered in 1998 (Sonesson et al., 2000) , and its basic pharmacology was first presented at scientific meetings Waters et al., 2002) . Our paper brings these results together with further data to provide an improved understanding of the essential pharmacology of pridopidine in particular.
Recent in vitro investigations with pridopidine have revealed further properties that distinguish it from other compounds that act primarily at dopamine D 2 receptors. Although pridopidine does not have an appreciable intrinsic activity in vitro (Tadori et al., 2007) or in vivo (Natesan et al., 2006) , it has a higher in vitro affinity to the activated state of the dopamine D 2 receptor (D 2 High ) compared with the low-affinity state (Seeman et al., 2009; Waters et al., 2009b; Pettersson et al., 2010) . Preferential interaction with D 2 High has previously been hypothesized to be a discrete property for compounds that display intrinsic activity at dopamine D 2 receptors; that is, full and partial agonists (George et al., 1985; Seeman et al., 2003) . In addition, the functional antagonism by pridopidine at dopamine D 2 receptors is fully surmountable by dopamine, and the fast recovery of receptor responsiveness to dopamine after washout of pridopidine suggests that it has fast-off dissociation kinetics at the dopamine D 2 receptor (Dyhring et al., 2010; Waters et al., 2009a) .
Antagonistic-like interaction of pridopidine with dopamine D 2 receptors
Treatment with pridopidine led to significantly increased metabolism of dopamine in the major dopamine projection areas of the brain, as indicated by increased dialysate levels of the dopamine metabolites DOPAC and HVA. The ED 50 value of 81 μmol/kg (95% CI: 71-99) we obtained for an increase of ex vivo tissue striatal DOPAC, was similar to the ED 50 value of 60 μmol/kg (95% CI: 36-83) previously reported for striatal dopamine D 2 receptor occupancy of pridopidine (Natesan et al., 2006) . Increased synaptic concentration and metabolism of dopamine with pridopidine is also suggested by the increase in extracellular concentrations of dopamine in striatal dialysates, in combination with reduced ex vivo striatal tissue levels of dopamine. Moreover, the level of 3-MT in striatal dialysates, which reflects postsynaptic degradation of synaptically released dopamine, also increased. Notably, dopamine D 2 receptor antagonists induce analogous neurochemical effects in the striatum (Westerink et al., 1998; Westerink and Korf, 1976) , both with respect to the pattern of increased dopamine and 3-MT, but even more so with respect to the quantitative and temporal increase in DOPAC and HVA.
Marked regional differences in the effects of dopamine D 2 receptor antagonists on extracellular levels of dopamine have been reported (Moghaddam and Bunney, 1990; Westerink et al., 2001) . The effects of the atypical antipsychotic clozapine on dialysate dopamine were smaller in the dorsal striatum than in the cortex, whereas the typical antipsychotic haloperidol had only limited effects on dialysate dopamine in the prefrontal cortex. Systemic administration of pridopidine induced a robust and rather homogenous increase in extracellular dopamine across regions, with slightly larger increases observed in the prefrontal cortex. The atypical antipsychotic aripiprazole, a partial agonist at the dopamine D 2 receptor, has been described as a dopamine system stabilizer (Hirose and Kikuchi, 2005) but it produces a different pattern of neurochemical effects in the dopamine system to pridopidine. Aripiprazole does not increase extracellular dopamine in either striatum or medial prefrontal cortex, and it has only moderate effects on DOPAC and HVA in these regions (Jordan et al., 2004; Semba et al., 1995) . Furthermore, striatal tissue dopamine and HVA levels remain unchanged even at cataleptic doses of aripiprazole (Nakai et al., 2003) .
Rats treated with pridopidine had increased extracellular levels of noradrenaline in the prefrontal cortex, nucleus accumbens and dorsal striatum. The mean increase in noradrenaline extracellular levels was most prominent in dorsal striatum; however, baseline levels were low and near the detection limit of the method used. In the cortex, the basal levels of noradrenaline were higher, and changes were more readily quantified. Notably, rats treated with pridopidine showed decreased levels of noradrenaline in ex vivo cortical tissue homogenates, and increased extracellular levels in prefrontal cortex, supporting enhanced release of noradrenaline, even at the lowest doses tested (3.7 and 5.6 μmol/kg, respectively). The effects on the 5-HT system were qualitatively similar but of limited magnitude. The atypical antipsychotic olanzapine induces regional effects on extracellular dopamine, noradrenaline and 5-HT levels (Li et al., 1998) that are in general similar to those induced by pridopidine in the present study. Indeed, the positive results obtained with pridopidine in the tail suspension test may be related to these increases in extracellular dopamine and noradenaline. Dopaminergic and noradrenergic agents, including the dual-acting noradrenaline and dopamine re-uptake inhibitors, have demonstrated antidepressant activity in the absence of any serotonin function, by treating symptoms associated with a reduced positive affect (Nutt et al., 2007) . With respect to the somewhat similar neurochemical effects induced by olanzapine and pridopidine, it is noteworthy that olanzapine is used clinically, in combination with fluoxetine, for the acute treatment of depressive episodes associated with bipolar I disorder and treatment-resistant major depressive disorder (Croxtall and Scott, 2010) .
Behavioural stabilizing effect of pridopidine and the putative role of dopamine D 2 receptor interactions
Environmental stimuli, such as a novel cage, induce an increase of both cortical and subcortical extracellular dopamine (Feenstra et al., 2000) . In our normal state experiments, the rats were introduced to a novel cage (the motility meter arenas) 4 min after pridopidine administration. Hence, during the first minutes of these normal state experiments, locomotor activity and extracellular dopamine would both be expected to be elevated compared with rats that are habituated to their environment. In the habituated-state experiments, pridopidine induced a moderate but definite stimulation of motor activity, whereas stimulation of motor activity was not evident during the first 15 min of the normal state experiments. Furthermore, in preclinical models of hyperlocomation, due to either hyper-dopaminergia or hypoglutamatergia, pridopidine displayed dose-dependent reductions of locomotor activity. Hence, the effects of pridopidine were state dependent (see also (Natesan et al., 2006; Pettersson et al., 2010) ).
The behaviour stabilizing effect of pridopidine is not explained solely by the specific interaction with dopamine D 2 receptors. In vitro data on interactions of pridopidine at the receptor level, such as surmountable and fast-off receptor kinetics, may account for the lack of reduction of spontaneous locomotor activity over a wide dose range. The increase in motor activity in habituated animals may also be regarded as an effect of the blockade of the dopamine D 2 High receptors on the presynaptic site, leading to moderately increased levels of dopamine in the synapse, subsequently stimulating postsynaptic dopamine D 2 receptors and inducing an increase in motor activity, provided that dopamine D 2 receptor affinity is not too high (see ). However, because data support activation of dopamine, noradrenaline and glutamate systems in the cortex by pridopidine, interactions with these systems may underlie the differences in vivo versus typical, neuroleptic-like dopamine D 2 receptor antagonists. Pridopidine, but not the dopamine D 2 receptor antagonist haloperidol, significantly inhibited amphetamine-induced hyperactivity in dopamine D 2 receptor knockout mice ). Hence, the reductions of locomotor activity in the hyperactive states could be explained, in part, by the cortical activation profile displayed by pridopidine. An increase in cortical noradrenaline (e.g. by alpha 2 adrenoceptor blockade) has been suggested to augment prefrontal dopamine functioning (Svensson, 2003) and adjunctive treatment with the alpha 2 adrenoceptor antagonist idazoxan improves antipsychotic efficacy in preclinical models (Hertel et al., 1999; Marcus et al., 2009 ) compared with dopamine D 2 receptor antagonists alone. In vitro, the combination of idazoxan with the dopamine D 2 receptor antagonist raclopride has been shown to cause a dopamine D 1 receptor-mediated facilitation of glutamate transmission in rat prefrontal pyramidal cells (Marcus et al., 2005) . Increased expression of Arc mRNA in rat cortex after administration of pridopidine, interpreted as increased synaptic glutamate activation of ionotropic NMDA receptors (Waters et al., 2009a) , could possibly be dependent primarily on the cortical increase in dopamine and noradrenaline. Increased cortical activation would strengthen cortical-striatal feedback regulation of psychomotor activity (Alexander et al., 1986) , leading to behavioural normalization of hyperactive states (Tekin and Cummings, 2002) . Glutamate influence on psychomotor functions in rodents is supported by data showing that LY404039, a glutamate receptor mGlu2/3 agonist, inhibits D-amphetamine-induced hyperactivity without sedative effects (Rorick-Kehn et al., 2007 )a similar effect to that seen with pridopidine.
Taken together, these results suggest that the psychomotor stabilizing effects of pridopidine may be dependent on its dual effects: the functional antagonism of subcortical dopamine transmission and strengthening of cortical glutamate transmission. The properties of dopaminergic stabilizers should therefore be regarded as an in vivo phenomenon, dependent on the effects in the corticosubcortical brain circuitries not revealed at the receptor level in vitro.
Clinical implications of the pharmacological profile
The preclinical profile of pridopidine includes the potential to stabilize motor function not only in hyperactivity, but also in states of hypoactivity. Furthermore, pridopidine displays antidepressant potential, as indicated by the tail suspension test data. It has been suggested that facilitation of prefrontal cortical dopamine levels, leading to stimulation of dopamine D 1 receptors, could attenuate some cognitive impairments associated with deficits in NMDA receptor function (Krystal et al., 2005) . Hence the increased extracellular concentrations of dopamine in the prefrontal cortex induced by pridopidine, in combination with the putative enhanced activation by pridopidine of synaptic NMDA receptors in the cortex, imply it could be beneficial for restoring impaired cortical activity. Indeed, pridopidine has shown beneficial effects in NMDA receptor antagonist rat models of cognitive and negative symptoms of schizophrenia (Nilsson et al., 2004; Rung et al., 2005) . Huntington's disease leads to damage of neurons in both the striatum and the cortex, causing regional hypo-and hyperactivity in the dopamine systems. Symptoms of HD include severe motor disturbances (lack of voluntary movements as well as presence of involuntary movements), cognitive impairment and psychiatric characteristics, including psychosis and depression. Thus, the in vivo pharmacological-effect profile of pridopidine suggests it may have significant benefits on the main symptom domains in HD. In an early study in HD, pridopidine was associated with improvements in voluntary motor performance, with no change in involuntary movement (Tedroff et al., 2009 ).
